Skip to main content
. Author manuscript; available in PMC: 2010 Apr 1.
Published in final edited form as: J Thorac Oncol. 2009 Apr;4(4):448–454. doi: 10.1097/JTO.0b013e31819c78fb

Figure 6. Inhibition of AKT and Bcl-xL.

Figure 6

A) Basal expression of pS473-AKT, AKT, Bcl-XL and Bcl-2 by Western blotting in a panel of lung cancer cell lines. B) A549 cells were incubated with increasing concentrations of PP2 for 24 hours, followed by Western blotting for pS473-AKT, AKT, Bcl-XL and Actin. C) A549 cells were incubated with AZD0530 for 24 hours at the doses indicated, followed by Western blotting for pS473-AKT, AKT, Bcl-XL and Actin.

HHS Vulnerability Disclosure